Immune
The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial
Iino S, Toyota J, Kumada H, et al. · J Viral Hepat · 2005
PMID: 15850471 · DOI: 10.1111/j.1365-2893.2005.00586.x
Summary
Randomized clinical trial in 316 Japanese adults with chronic hepatitis B comparing subcutaneous thymosin alpha 1 0.8 vs 1.6 mg twice weekly for 24 weeks. Endpoints: ALT normalization, HBV-DNA and HBeAg clearance at 72 weeks.
Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.
Compounds referenced in this study
- View product →Thymosin Alpha-1 5mg28-residue acetylated thymic peptide studied in immune-modulation research.
Guides covering this compound
More Immune citations
- The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trialCrit Care · 2013
- The efficacy and safety of thymosin alpha-1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trialBMJ · 2025
- Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trialLiver · 1996